Biotech ETFs surge with distinct strategies: equal-weight bets on breakthroughs, cap-weight offers stability.

Biotech ETFs have outperformed the market, with the State Street SPDR S&P Biotech ETF up 40.80% and the iShares Biotechnology ETF up 33.95% over the past year. The State Street fund uses an equal-weight strategy, giving smaller companies more influence and higher volatility but greater upside potential from breakthroughs. In contrast, the iShares fund is market-cap weighted, concentrating on large, stable firms like Gilead and Amgen, offering steadier returns. Analysts expect biotech growth in 2026 driven by rate cuts, mergers and acquisitions, and AI-driven drug discovery, making the choice between these ETFs a matter of risk appetite and investment style.